Iovance Biotherapeutics, Inc. Stock News

SAN CARLOS, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor inf

SAN CARLOS, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor inf

Iovance Biotherapeutics is on the cusp of its first FDA approval for its TIL therapy in the treatment of metastatic melanoma. The company operates on the belief that adoptive cell therapy can effectiv

Iovance Biotherapeutics' lifileucel, a tumor infiltrating lymphocyte product, is under FDA review for the treatment of advanced melanoma. The FDA decision on the biologics license application for lifi

SAN CARLOS, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor in

Iovance Biotherapeutics shows promise in T-cell therapies for solid tumors despite FDA delays; robust financials with a cash runway of 13.1 months. Insider buying and strategic ATC investments indicat

Iovance's lead therapy lifileucel still has a chance at an early approval to treat advanced melanoma. Lifileucel is also being tested to treat several other types of cancer.

At first glance, the latest regulatory news is a setback. However, there were more than a few silver linings in this development.

Iovance Biotherapeutics (NASDAQ: IOVA) stock price defied gravity on Friday as investors cheered the latest FDA update about its drug. The shares jumped by more than 15% even as the Nasdaq 100 and S&P

Iovance (IOVA) rises despite the FDA's postponement of the decision date regarding the regulatory filing for its lead candidate, lifileucel, to treat advanced melanoma due to resource constraints.

Iovance Biotherapeutics (NASDAQ:IOVA) stock looked to soar at Friday's market open, recovering from a steep loss on Thursday after the company said the US Foood and Drug Administration (FDA) needed mo

One analyst downgraded his price target for the stock on Wednesday. Iovance's lead therapy is Lifileucel, which treats multiple cancer types.

SAN CARLOS, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor in

Iovance Biotherapeutics, Inc. has a deep pipeline of cancer immunotherapies, but has faced delays and issues with duration of response. The company's lead asset, lifileucel, is being tested in multipl

Investing in biotech stocks is challenging even when you're investing in established companies with commercially available drugs and expansive pipelines. And investing in up-and-coming biotech stocks